araag2/HINT huggingface dataset:
Clinical trial NCT00197145 (phase 3, status: terminated)
Conditions: infection, human immunodeficiency virus i
ICD codes: Z21
Drugs: gw873140
SMILES: [H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-infected.

          -  Screening viral load at least 5000copies/mL.

          -  R5-tropic only virus at screening.

          -  Total prior antiretroviral experience of at least 3 months and documented resistance
             to at least one drug in each of the following classes: nucleoside reverse
             transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors
             (NNRTI), and protease inhibitors (PI).

          -  Stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks
             before screening.

          -  Able to receive a ritonavir-boosted protease inhibitor during treatment studies.

          -  Women of childbearing potential must use specific forms of contraception.

        Exclusion criteria:

          -  Acute laboratory abnormalities.

          -  History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any
             chronic liver disease. Screening liver function tests will be used to determine
             eligibility.

          -  R5/X4-tropic, X4-tropic only, or non-phenotypeable virus at screening.

          -  Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of
             treatment study.

          -  Pregnancy or breastfeeding women.

          -  Recent participation in an experimental drug trial.

          -  Prior use of a CCR5 or CXCR4 antagonist.

          -  Significant ECG abnormalities or significant history of active pancreatitis,
             hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe
             illness.

          -  Current use of certain medications may exclude participation in this study.

          -  Additional qualifying criteria and laboratory test requirements to be assessed by
             study physician.
Clinical trial NCT01025817 (phase 3, status: completed)
Conditions: kidney transplant
ICD codes: T86.11, T86.12, T86.13, Z94.0, T86.10, T86.19, Z48.22
Drugs: everolimus and tacrolimus, mycophenolate mofetil and tacrolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion criteria:

          -  Male or female renal recipients 18-70 years of age undergoing kidney transplantation,
             either primary or re-transplant;

          -  Recipient of a cadaveric, deceased donor (including expanded criteria donor organs and
             deceased donor organs after cardiac death), living unrelated or non-HLA identical
             living related donor kidney;

          -  Graft must be functional (producing greater than or equal to 100 ml of urine within 24
             hours after transplantation) at time of randomization.

        Exclusion criteria:

          -  Donor organ with a cold ischemic time > 30 hours;

          -  Males or females who produce less than 100 ml of urine in the first 24 hours
             post-transplantation;

          -  Males or females who are recipients of ABO incompatible transplants, or T cell, or B
             cell crossmatch positive transplant;

          -  Males or females with severe total hypercholesterolemia or total hypertriglyceridemia
             (Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable);

          -  Males or females who have any surgical or any medical condition, such as severe
             diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, which in the
             opinion of the investigator, might alter the absorption, distribution, metabolism
             and/or excretion of study medication.

        Other protocol related inclusion/exclusion criteria may apply.
Clinical trial NCT00676845 (phase 3, status: completed)
Conditions: metabolic syndrome, hypertension
ICD codes: E88.81, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: olmesartan medoxomil, placebo, olmesartan medoxomil, olmesartan medoxomil
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female outpatients

          -  Age greater than or equal to 18 years and less than or equal to 75 years

          -  Hypertension and metabolic syndrome defined, according to the ATP III/IDF 2005 and
             ESH/ESC 2007 definitions, as BP greater than or equal to 130/85 mmHg and <150/95 mmHg
             (i.e. untreated high normal BP or "low range" mild hypertension) and at least 2 of the
             following traits at:

          -  Abdominal obesity (waist circumference >102 cm for men and >88 cm for women)

          -  Triglyceride level greater than or equal to 150 mg/dL

          -  High density lipoprotein (HDL) <40 mg/dL for men and <50 mg/dL for women

          -  Fasting blood glucose greater than or equal to 110 mg/dL and <126 mg/dL (i.e. no type
             2 diabetes)

          -  No anti-hypertensive treatment or treatment with only one anti-hypertensive medication
             within the last 3 months. Note: treatment with angiotensin II receptor blockers
             (ARB)or angiotensin-converting enzyme inhibitors (ACE) is not allowed within the last
             6 months.

        Exclusion Criteria:

          -  Pregnant or lactating female (prerequisite for female subjects of childbearing
             potential: adequate contraception)

          -  Type 1 and type 2 diabetes

          -  "High range" mild hypertension (i.e. systolic blood pressure [SBP]: 150 - <160 mmHg
             and /or diastolic blood pressure [DBP]: 95 - <100 mmHg)

          -  Moderate (SBP: 160 - 179 mmHg and DBP: 100 - 109 mmHg), severe (SBP: greater than or
             equal to 180 mmHg and/or greater than or equal to 110 mmHg), or resistant
             (hypertension resistant to treatment)hypertension

          -  Secondary hypertension of any aetiology, such as renal disease, pheochromocytoma, or
             Cushing's syndrome
Clinical trial NCT01613482 (phase 3, status: terminated)
Conditions: breast cancer, metastasis, sur-expressing her2-neu
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, other chemotherapy in association with trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and
             amplification on FISH or CISH, SISH)

          -  Visceral metastasis, only or multiple

          -  First line metastasis treatment by Trastuzumab in association with chemotherapy

          -  Good general conditions: OMS=<2 or Karnofsky >=70%

          -  Age > 18 years and < 70 years

          -  Life expectancy >=3 mois

          -  No Trastuzumab since more of 6 months

          -  No cerebral metastasis (MRI)

          -  Efficacy contraception for women with genital capacities

          -  Consent signed by the patient

        Exclusion Criteria

          -  Contraindication to IRM

          -  Psychiatric decease

          -  Prior cerebral radiotherapy,

          -  Geographical constraint, compromising the fallow of patients

          -  Infectious or other serious pathology, likely to stop the treatment

          -  Positive serology (HIV, hBC, hBS)

          -  Inclusion in an other clinical trial or in the 4 weeks before th inclusion

          -  Pregnant or breastfeeding women
Clinical trial NCT00460746 (phase 3, status: completed)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: tmc125, darunavir; ritonavir
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Documented HIV-1 positive

          -  History of drug resistance or antiretroviral failure while receiving each of three
             drug classes: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside
             Reverse Transcriptase Inhibitors (NNRTIs) and (protease inhibitors) PIs

          -  On a PI containing regimen with enfuvirtide with HIV viral load (VL) < 400 copies/mL
             for 6 months or longer

          -  Continuously using the same PI regimen for 4 months prior to Screening

          -  Decline to continue enfuvirtide or their physician recommends discontinuation due to
             injection site reactions that persist despite optimal technique and training with
             available methods of administration or loss of sites for injection due to tissue
             nodules and hardening.

        Exclusion Criteria:

          -  No use of any drug contraindicated in the current US package insert for PREZISTA
             (darunavir) or in the investigators brochure for TMC125

          -  No prior or current therapy with PREZISTA (darunavir) or TMC125

          -  No prior genotypic results demonstrating 3 or more darunavir resistance-associated
             mutations associated with diminished response to darunavir (V11I, V32I, L33F, I47V,
             I50V, I54L, I54M, G73S, L76V, I84V or L89V). Patients with > 3 darunavir
             resistance-associated mutations with available darunavir phenotypes, may be enrolled
             if the resistance phenotype demonstrates: Fold Change (FC) <10 to darunavir by
             PhenoSense GT (Monogram Biosciences) or FC <10 to darunavir by Antivirogram (Virco,
             BVBA) or FC <3.4 to darunavir by vircoTYPE (Virco BVBA)

          -  AST or ALT >5 times ULN

          -  Calculated CrCl < 30 ml/min.
Clinical trial NCT00281593 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan, ramipril
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients >=18 years of age with Stage I or II hypertension defined as:

          -  a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg Main

        Exclusion Criteria:

          -  Pregnant

          -  breast-feeding

          -  unwilling to use birth control during the study

          -  secondary hypertension

          -  SBP>=180 mmHg

          -  DBP>=120 mmHg

          -  severe renal dysfunction

          -  hepatic insufficiency

          -  stroke within the last 6 months

          -  myocardial infarction, cardiac surgery, percutaneous transluminal coronary
             angioplasty, unstable angina or coronary artery bypass graft within the past three
             months

          -  unstable or uncontrolled diabetes

          -  history of angioedema of either of the study drugs, and hypersensitivity to the study
             drugs.
Clinical trial NCT00219596 (phase 3, status: completed)
Conditions: glaucoma, open angle, ocular hypertension
ICD codes: H40.053, H40.051, H40.052, H40.059
Drugs: xalacom, unfixed latanoprost and timolol
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  patients with open-angle glaucoma or ocular hypertension

        Exclusion Criteria:

          -  closed/barely open anterior chamber angle or a history of acute angel closure glaucoma

          -  Ocular surgery within 3 months
Clinical trial NCT00498615 (phase 3, status: completed)
Conditions: raynaud, scleroderma
ICD codes: L94.1, L94.0
Drugs: fasudil
SMILES: O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of scleroderma

          -  definite Raynaud's

        Exclusion Criteria:

          -  symptomatic orthostatic hypotension

          -  evidence of current malignancy

          -  active ischemic digital ulcer and/or tissue gangrene

          -  history of sympathectomy at any time

          -  upper extremity deep vein thrombosis or lymphedema within 3 months of the study

          -  recent surgical procedure requiring general anesthesia

          -  current alcohol or illicit drug use

          -  use of any investigational drug within 30 days of the study sessions

          -  pregnancy or current breast feeding

          -  subjects felt by the investigators to active disease that would affect their ability
             to safely participate in the study.
Clinical trial NCT00002523 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, leucovorin calcium
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed resectable adenocarcinoma of the rectum

               -  Any grade

               -  Tumor macroscopically within 15 cm of anal margin on rigid rectoscopy

               -  Tumor tethered or partially fixed on digital rectal exam and/or T3-4 on rectal
                  ultrasound

          -  No acute or subacute bowel obstruction without colostomy diversion

          -  No chronic inflammatory disease of the ileum and/or colon

          -  No primary adenocarcinoma of the anal canal

          -  No distant metastasis

        PATIENT CHARACTERISTICS:

        Age:

          -  80 and under

        Performance status:

          -  WHO 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count greater than 2,000/mm^3

          -  Platelet count greater than 130,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine less than 1.36 mg/dL

        Cardiovascular:

          -  No angina pectoris

        Other:

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             uterine cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior biologic therapy for adenocarcinoma of the rectum

        Chemotherapy

          -  No prior chemotherapy for adenocarcinoma of the rectum

        Endocrine therapy

          -  No prior endocrine therapy for adenocarcinoma of the rectum

        Radiotherapy

          -  No prior radiotherapy for adenocarcinoma of the rectum

        Surgery

          -  No prior surgery for adenocarcinoma of the rectum
Clinical trial NCT01091168 (phase 3, status: completed)
Conditions: breast cancer, metastases
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vinflunine, alkylating agent of physician choice registered in cancer
SMILES: CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:(main conditions)

          -  Female patients 18 to 75 years of age with metastatic breast cancer
             histologically/cytologically confirmed not amenable to curative surgery or
             radiotherapy and who have received at least two prior chemotherapy regimens including
             anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate
             for these drugs,

          -  Karnofsky performance score of at least 70 %, adequate haematological, hepatic and
             renal functions and ECG without clinically relevant abnormality.

        Exclusion Criteria:

          -  Concurrent serious uncontrolled medical disorder,

          -  known or clinical evidence of brain metastases or leptomeningeal involvement,

          -  pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,

          -  history of second primary malignancy,

          -  HIV infection, preexisting neuropathy,

          -  pregnancy or breast feeding.
Clinical trial NCT00069745 (phase 3, status: completed)
Conditions: prostate cancer, hormone refractory prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: satraplatin, prednisone
SMILES: N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Stage D2 metastatic prostate cancer

          -  Progression after one prior chemotherapy

          -  ECOG Performance status equal / less than 2

          -  Life expectancy > 3 months

          -  Surgical or medical castration

          -  Adequate bone marrow, hepatic and renal functions

          -  Informed consent

        Exclusion Criteria:

          -  More than one prior chemotherapy

          -  Prior platinum containing compounds

          -  Prior malignancy

          -  Prior significant RT/radionuclide therapy

          -  Major GI surgery or GI disease affecting absorption

          -  Disease with contraindication to steroids

          -  Brain metastases
Clinical trial NCT01565707 (phase 3, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: solifenacin succinate suspension, placebo
SMILES: O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Written Informed Consent has been obtained

          -  OAB (symptoms of urgency) according to International Children's Continence Society
             (ICCS) criteria

          -  Daytime incontinence with at least 4 or more episodes of incontinence confirmed by 7
             day participant diary

        Main Exclusion Criteria:

          -  Daily voiding frequency less than 5

          -  Extraordinary daytime urinary frequency according to the International Children's
             Continence Society (ICCS) definition

          -  Uroflow indicative of pathology other than OAB

          -  Maximum voided volume (morning volume excluded) > expected bladder capacity for age
             [(age +1) x 30] in ml or a maximum voided volume (morning volume excluded) above 390
             ml

          -  Post Void Residual (PVR) > 20 ml

          -  Monosymptomatic enuresis

          -  Polyuria defined as > 75 ml/kg/b.w./24 hours

          -  Dysfunctional voiding

          -  Congenital anomalies affecting lower urinary tract function

          -  Current constipation

          -  Current Urinary Tract Infection (UTI)

          -  Catheterization within 2 weeks prior to screening
Clinical trial NCT02142556 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: administration of quetiapine xr
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  The participants who were aged from 20 to 65 years and met the diagnosis of
             schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders,
             fourth edition, text revision (DSM-IV-TR) were eligible for the recruitment to the
             clinical trial.

          -  They also fulfilled the criteria including having a score of 4 (moderate) or greater
             on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive
             Symptom Subscale and needed to switch from previous antipsychotics due to insufficient
             efficacy or insufficient tolerability.

        Exclusion Criteria:

          -  Any DSM-IV-TR Axis I disorder other than schizophrenia, except comorbid
             obsessive-compulsive disorder, anxiety disorder, eating disorders or impulse control
             disorders if they had been stable and had not been primary focus of treatment over the
             previous 6 months

          -  An imminent risk of suicide or a danger to self or others

          -  Pregnancy or lactation

          -  Intolerance or lack of response to quetiapine IR

          -  Use of cytochrome P450 3A4 inhibitors or inducers in the 14 days preceding enrolment

          -  Administration of a depot antipsychotic injection within one dosing interval before
             recruitment

          -  Unstable or inadequately treated medical illness as judged by the investigator.
Clinical trial NCT00101426 (phase 3, status: completed)
Conditions: diabetic neuropathy
ICD codes: E10.40, E11.40, E13.40, E10.43, E11.43, E13.43, E08.40
Drugs: ranirestat, (as-3201)
SMILES: FC1=C(CN2C(=O)C3=CC=CN3[C@@]3(CC(=O)NC3=O)C2=O)C=CC(Br)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with the following may enter:

        Clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical
        distal Diabetic Sensorimotor Polyneuropathy with diagnosis by Nerve Conduction Tests and/or
        Quantitative Sensory Test.

          -  18 to 70 years old of either sex and any race

          -  Type I or Type II, insulin-dependent or non insulin-dependent diabetes for at least
             six months prior to study entry

          -  Healthy in general

          -  No hospitalizations for diabetic control or episodes of ketoacidosis for three months
             prior to screening

          -  Female patients of childbearing potential must have a negative serum pregnancy test

        Exclusion Criteria:

          -  Known non-diabetic causes of neuropathic symptoms

          -  Diabetic patients with no neuropathy or severe neuropathy

          -  Used any Aldose Reductase Inhibitors within one year of screening

          -  Clinically significant illness including unstable cardiac, pulmonary, hematologic,
             hepatic, renal, or neoplastic disease

          -  A history of systemic carcinoma within five years of screening

          -  A history of epilepsy or serious head injury

          -  A history or evidence of drug or alcohol abuse

          -  Test positive at screening for hepatitis B surface antigen or hepatitis C antibody or
             have a history of a positive result, or patients with evidence of significant hepatic
             insufficiency

          -  A history of known or suspected diagnosis of AIDS, or have tested seropositive for HIV
             antibody or antigen previously